Inhibition of Apoptosis in Experimental Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000008
Summary
In glaucoma, the loss of retinal ganglion cells (RGC) proceeds by a mechanism known as apoptosis. Apoptosis is an organized, or programmed, form of cell death that requires the action of a series of proteases (proteins that chop up other proteins) called caspases. In animal models of glaucoma, the protease Caspase-3 is found to be activated in RGCs, where it also cleaves a molecule called amyloid precursor protein (APP). APP is important in Alzheimer’s disease (AD) as well as in glaucoma. In fact, the excessive production of smaller fragments of APP, called amyloid beta, is a hallmark of AD and is thought to be toxic to neurons. Dr. McKinnon is interested in the fact that these two different neurodegenerative diseases, glaucoma and AD, share some key features. He is examining the apoptotic death of RGCs and the possible role of APP in more detail. An understanding of RGC apoptosis could be important in devising protective strategies for preventing glaucomatous damage, and these studies may also illuminate general features of nerve cell death in the central nervous system, making them relevant to other neurodegenerative diseases like AD.
Related Grants
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Novel Visualization of Aqueous Outflow: Uncovering Glaucoma Mechanisms and Therapeutic Targets
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Tyson Kim, MD, PhD
Current Organization
University of California, San Francisco
Novel Visualization of Aqueous Outflow: Uncovering Glaucoma Mechanisms and Therapeutic Targets
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Tyson Kim, MD, PhD
Current Organization
University of California, San Francisco